Llwytho...
Decitabine/Cedazuridine: First Approval
A fixed dose oral combination (FDC) of decitabine and cedazuridine (Inqovi(®)), is being developed by Astex Pharmaceuticals (a subsidiary of Otsuka Pharmaceuticals) for the treatment of various cancers like myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML), acute myeloid leuka...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Drugs |
|---|---|
| Prif Awdur: | |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Springer International Publishing
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7708383/ https://ncbi.nlm.nih.gov/pubmed/32860582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01389-7 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|